NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Over the last decade, genomics and proteomics have been used as key tools to discover potential drug targets and to better understand the complexities of biology. To balance research in these areas, epigenetics offers a potential opportunity in understanding the basis of various diseases in a different approach. Thus, epigenetics is study of heritable changes in genome function and gene expression had opened the new gate of biology to understand the basis of diseases and presents incredible opportunities for disease diagnosis and drug discovery.
Report covers the market by therapeutics sector in oncology conditions, non-oncology indications and personalized medicine. The report also covers the market by research and diagnostics sector in gene regulation studies, biomarker detection and drug discovery. In addition, it also includes the factors driving and restraining the market and covers the market scenario in the U.S., Europe, Asia and the Rest of the World (ROW). This report will provide the company profiles of key companies along with the competitive analysis.
The Global Epigenetics market is showing a double digit growth (CAGR 25%) due to supportive factors such as, (i) huge amount of funds and investments, (ii) increasing partnerships and collaborations, and (iii) rapid screening tools. Epigenetics is used in the identification of new epigenetic biomarkers, which will aid in better diagnosis and prognosis of diseases. While there are factors favoring the market growth, there are concerns such as change in re-imbursement systems and lack of predictive markers holding back the growth of this market. However, the positive aspects in this field may very well offset the market restraints to aid the market grow at an exceptional rate.
The report also profiles leading participants of this industry with their recent developments and other strategic industry activities. These include: CH3 BioSystems (U.S.), Eisai (Japan), Covaris Inc. (U.S.), Epiontis (Germany), RiboMed Biotechnologies (U.S.), 4SC (Germany), Novus Biologicals (U.S.), Merck Millipore (U.S.), CellCentric (U.K.), Celgene (U.S.), Karus Therapeutics (U.K.), EpiTherapeutics (Denmark), Resverlogix (Canada), Epizyme (U.S.), Glaxosmithkline (U.K.), Epigenomics (Germany).
Scope of the Report This technology report categorizes the market for epigenetics by geographical region (including the important countries in each region), applications, and epigenetic mechanisms, forecasting the market value in revenue by analyzing the current and future trends in research, diagnostics and therapeutics industries.
A detailed description of the global technology developments and evolving trends in the epigenetics field with key prominence on research innovations, collaborative efforts and focused research through consortiums dedicated for epigenetics.
A close view on the drug development for treatment of various diseases by providing the details and status of current epigenetic drugs in pipeline.
An impact analysis of major drivers, restraints and challenges influencing the adoption and growth of epigenetics market during the period from 2012 to 2017.
Market size - Global market forecast for 2012-2017, including demand side analysis and strategic recommendations for technology/product developers.
Competitive landscape based on the analysis of key patents and research publications that gives an insight into prominent activities and global participants.
1. INTRODUCTION 13-18 1.1 KEY TAKE-AWAYS
1.2 REPORT SCOPE
1.3 RESEARCH METHODOLOGY
1.4 KEY DATA POINTS FROM PRIMARY AND SECONDARY SOURCES
2. EXECUTIVE SUMMARY 19-21 3. EPIGENETICS – TECHNOLOGY LANDSCAPE ANALYSIS 22-60
3.1 TECHNOLOGY OVERVIEW3.2 TECHNOLOGY EVOLUTION – MILESTONES IN EPIGENETICS3.3 EPIGENETIC MECHANISMS3.3.1 DNA METHYLATION3.3.2 HISTONE MODIFICATIONS3.3.3 RNA INTERFERENCE3.4 TECHNOLOGY VALUE CHAIN ANALYSIS3.5 APPLICATIONS3.5.1 THERAPEUTICS220.127.116.11 ONCOLOGY CONDITIONS18.104.22.168 NON-ONCOLOGY INDICATIONS22.214.171.124 PERSONALIZED MEDICINE3.5.2 RESEARCH AND DIAGNOSTICS126.96.36.199 GENE REGULATION STUDIES188.8.131.52 BIOMARKER DETECTION184.108.40.206 DRUG DISCOVERY3.6 EPIGENETICS – TECHNOLOGY INNOVATIONS AND PRODUCTS WITH APPLICATIONS3.7 CURRENT SCENARIO IN EPIGENETICS
4. EPIGENETICS – MARKET LANDSCAPE ANALYSIS 61-79
4.1 EPIGENETICS MARKET SIZE – POTENTIAL ADDRESSABLE MARKET4.2 GLOBAL EPIGENETICS MARKET SEGMENTATION4.3 GLOBAL MARKET REVENUE FORECAST (2012-2017)4.3.1 BY GEOGRAPHY4.3.2 BY APPLICATIONS4.3.3 BY EPIGENETIC MECHANISMS4.4 MARKET SHARE OF COMPANIES4.5 MARKET DYNAMICS 4.5.1 DRIVERS 4.5.2 RESTRAINTS4.5.3 CHALLENGES
5. TECHNOLOGY INVESTMENT POTENTIAL 80-99
5.1 INVESTOR NETWORK5.1.1 SOME FUNDS AND INVESTMENTS BY PUBLIC FUNDING BODIES5.1.2 SOME FUNDS AND INVESTMENTS BY NON-GOVERNMENT ORGANIZATIONS (NGOs)5.1.3 SOME INVESTMENTS BY CORPORATE, PRIVATE AND EQUITY INVESTORS5.1.4 INSIGHTS ON CURRENT AND FUTURE TECH-INVESTMENT TRENDS5.1.5 FUNDING PATTERNS AND INVESTOR INCLINATION
5.2 INVESTMENT OPPORTUNITIES
5.2.1 EPIGENETIC TECHNOLOGIES AND PRODUCTS AVAILABLE FOR
LICENSING & ACQUISITION FOR STAKEHOLDERS
5.2.2 ANALYSIS OF POTENTIAL APPLICATION AREAS FOR TECHNOLOGY
INVESTMENT – BASED ON OPPORTUNITY STRATEGY EVALUATION (OSE) ANALYSIS
6. EPIGENETICS – TECHNOLOGY ADOPTION POTENTIAL AND DEVELOPMENT BY GEOGRAPHY 100-108 6.1 INTRODUCTION
6.2 NORTH AMERICA
6.6 DEMAND SIDE ANALYSIS
7. EPIGENETICS COMPETITIVE LANDSCAPE 109-123
7.1 KEY MERGERS AND ACQUISITIONS 7.2 PARTNERSHIPS AND COLLABORATIONS 7.3 THERAPEUTIC DRUGS IN PIPELINE7.4 WORLDWIDE CONSORTIUMS AND NETWORKS IN EPIGENETICS
8. INTELLECTUAL PROPERTY AND RESEARCH STRENGTH ANALYSIS 124-126 8.1 IP STRENGTH ANALYSIS OF EPIGENETICS BETWEEN 2008-2012
8.2 ANALYSIS OF RESEARCH STRENGTH FROM NCBI PUBMED PUBLICATIONS
9. ANALYST INSIGHTS AND RECOMMENDATIONS 127-130
9.1 ANALYST INSIGHTS9.2 ANALYST RECOMMENDATIONS9.3 OPEN OPPORTUNITY INVITATIONS IN THE FIELD FOR BUSINESS DEVELOPMENT
10. COMPANY PROFILES 131-143 10.1 4SC (GERMANY)
10.2 CELGENE (U.S.)
10.3 CELLCENTRIC (U.K.)
10.4 CH3 BIOSYSTEMS (U.S.)
10.5 COVARIS INC. (U.S.)
10.6 EISAI CO. LTD. (JAPAN)
10.7 EPIONTIS (GERMANY)
10.8 EPITHERAPEUTICS (DENMARK)
10.9 EPIZYME (U.S.)
10.10 KARUS THERAPEUTICS (U.K.)
10.11 MERCK MILLIPORE (U.S.)
10.12 RIBOMED BIOTECHNOLOGIES (U.S.)
11. APPENDIX 144-152 12. GLOSSARY 153-154LIST OF TABLES Table 1 Global Epigenetics Market Revenue, By Geography, 2012–2017 ($Million) 65
Table 2 Global Epigenetics Market Revenue, By Application Segments, 2012–2017 ($Million) 68
Table 3 Global Epigenetics Market Revenue, By Therapeutic Applications, 2012–2017 ($Million) 69
Table 4 Global Epigenetics Market Revenue, By Research & Diagnostics Applications, 2012–2017 ($Million) 70
Table 5 Global Epigenetics Market Revenue, By Epigenetic Mechanisms, 2012–2017 ($Million) 72
Table 6 Market Share of Companies based on Currently Available four Drugs 73
Table 7 Some Funds and Investments By Public Funding Bodies 83
Table 8 Epidemiology and Genomics Research Program (EGRP) Funding Details for Epigenetics 85
Table 9 NIH Funding Details for Epigenetics 86
Table 10 Some Funds and Investments By Non-Government Organizations (NGOs) 87
Table 11 Some Investments By Corporate, Private and Equity Investors 88
Table 12 Worldwide Incidence & Mortality of Selected Cancers (Cases/Year) 93
Table 13 Mergers and Acquisitions 110-113
Table 14 Partnerships and Collaborations 114-115
Table 15 Therapeutic Drugs in Pipeline 116-119
Table 16 Key Patents 146
Table 17 Different Types of Products for Epigenetic Mechanisms – DNA Methylation 147-149
Table 18 Different Types of Products for Epigenetic Mechanisms – Histone Modifications 150-151
Table 19 Different Types of Products for Epigenetic Mechanisms – RNA Interference 152
LIST OF FIGURES FIG 1 Global Market of Epigenetics 2012–2017 ($Million) 64
FIG 2 Global Epigenetics Market Revenue, By Geography, 2012–2017 ($Million) 66
FIG 3 Global Epigenetics Market Share – By Geography 67
FIG 4 Global Epigenetics Market Revenue, By Application Segments,2012-2017 ($Million) 68
FIG 5 Global Epigenetics Market Revenue, By Therapeutic Applications, 2012–2017 ($Million) 69
FIG 6 Global Epigenetics Market Revenue, By Research & Diagnostics Applications, 2012–2017 ($Million) 70
FIG 7 Global Epigenetics Market Share – By Applications 71
FIG 8 Global Epigenetics Market Revenue, By Epigenetic Mechanisms, 2012–2017 ($Million) 72
FIG 9 Market Share of Companies Based On Currently Available Four Drugs 73
FIG 10 Epidemiology and Genomics Research Program (EGRP) Funding Details For Epigenetics 85
FIG 11 NIH Funding Details For Epigenetics 86
FIG 12 Epigenetics, Year-wise Funding Patterns & Investment Forecast (2012–2017) 91
FIG 13 Current Funding Pattern By Investors For Epigenetics 91
FIG 14 Patents Published Between 2008-2012 125
FIG 15 PubMed Publications Between 2008-2012 126
FIG 16 PubMed Publications on Epigenetic Enzymes 2008-2012 126
Intl: +1 805-652-2626